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Absolute dose rate: Comparison of results and uncertainty 
analysis of a) using a chamber calibrated in air (A-20 from 
Standard Imaging calibrated on ADCL Wisconsin, USA) 
following the AAPM TG-61 protocol, and b) using a parallel 
plate chamber calibrated in water (TM34013 from PTW 
calibrated on PTW, Germany) following the IAEA TRS-398 
protocol. 
PDD: Using the parallel plate chamber on solid water. 
Leakage: Measurements at different levels with the primary 
beam blocked 
 The Esteya includes a specially designed QA tool that is 
connected to the exit of the X-ray tube. Each treatment day 
it is mandatory to perform a QA test before the first patient 
can be treated. This tool is composed of 26 diodes placed in 
two parallel planes, which are used to evaluate the output, 
flatness and percentage dose depth curve constancy at the 
same time. After the QA plan has been irradiated, the 
equipment console automatically shows the comparison with 
the reference values. Only if results are below an established 
tolerance level, the system allows patients to be treated. In 
addition, within a monthly basis, flatness, symmetry, 
penumbra, output and PDD are evaluated with film or high 
resolution array and parallel plate chamber on solid water. 
 Finally, the following clinical implementation aspects will be 
presented and discussed: depth evaluation (using High 
Frequency Ultrasound), margins and applicator selection, 
patient marking, patient set-up and treatment time 
calculation. 
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Background/Objective: Low and medium energy (kV) x-ray 
radiotherapy beams are still widely used for treatment, 
particularly for skin cancers and other relatively shallow 
lesions, and also more recently for ’electronic 
brachytherapy’ (Perez-Calatayud, this session).  Historically, 
kV beams have been used widely for radiobiology and related 
experiments, the results of which have been used to inform 
clinical radiotherapy practice, although the dosimetry has 
often been on less solid foundations than radiotherapy 
dosimetry. In the last ten years or so, since the increasingly 
wide availability of kV image guidance systems on clinical 
linacs, there has been a growing need for clear 
recommendations on kV beam dosimetry for these systems, 
where practical approaches have been developed which draw 
on both diagnostic radiology dosimetry and kV therapy beam 
dosimetry and with signficant contribution from MC modelling 
(Ding, this session).  Recently too, kV applications relevant to 
radiotherapy, in terms of supporting and developmental 
research, have included pre-clinical studies using small 
animal irradiators and microbeam methods, in both cases 
requiring small (or very small) kV beam dosimetry.  In general 
terms, the same quality standards are applicable in kV 
dosimetry as for high energy (MV) x-ray beams.  Thus, 
ideally, similar levels of precision and accuracy are required 
for treatment planning and delivery and hence similar levels 
of knowledge of beam characterisics and kV beam doses for 
both clinical and research uses, including for radiotherapy 
imaging beams.  Therefore, similar attention is necessary in 
choice of  instrumentation, experimental methods, beam 
calibration dosimetry, beam commissioning and quality 
assurance measurements, and their uncertainties.  kV beams 
should also be consisdered, as for MV beams, within the same 
general infrastructure of radiotherapy quality systems, 
clinical/quality audit and dosimetric audit.  
Overview Content: This overview considers the current 
situation in kV radiotherapy beam dosimetry and aims to 
cover: 
·       an outline of the specific requirements in kV dosimetry 
·       the instrumentation requirements for absolute and 
relative dose measurements in therapy beams 
·       the current dosimetry protocols and their similarities 
and differences, both for beam calibration protocols (in air 
and in phantom) and relative dosimetry recommendations 
·       phantoms and methods for measurements 
·       the likely uncertainties involved in methods and data 
·       the differences and similarities between dosimetry for 
kV beams when used for therapy or imaging 
·       the dosimetry methods used for kV CBCT 
·       MC in kV dosimetry, linking to Ding (this session) 
·       some comments on dosimetry needs and methods for 
novel kV applications, including  small animal systems and 
microbeams.  
Conclusions: The basis of kV dosimetry and the practical 
methods used are reasonably consistent with MV dosimetry, 
although uncertainties are typically greater.  Radiotherapy 
imaging dosimetry methods span different approaches which 
still needs further effort to  agree generally recommended 
and accepted guidelines.  Recent developments in pre-
clinical and microbeam applications have concentrated effort 
on small field kV dosimetry, which in turn also improves 
dosimetry for  standard clinical uses of kV radiotherapy 
beams.   All areas of kV beam dosimetry are benefiting 
greatly from MC modelling. 
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Introduction: The utilization of kV X-ray in image-guided 
radiotherapy (IGRT) has significantly improved the 
radiotherapy delivery accuracy and IGRT has become the new 
paradigm for patient positioning and target localization. Daily 
imaging procedures also add additional dose to the patients’ 
normal tissues. Knowledge of radiation dose resulting from a 
kV-CBCT scan and kV radiograph imaging procedures is 
important for clinicians in making informed decisions for 
treatment management and risk/benefit analysis.  
Purpose: The purpose of this presentation is  
1)      to describe the Monte Carlo simulation technique to 
generate kV beams from x-ray sources that are integrated to 
a radiotherapy treatment unit;  
2)      to show the beam characteristics of kV beams used in 
image guidance procedures;  
3)      to present the techniques to calculate dose to patients 
from kV-CBCT scans and kV radiograph imaging procedures by 
using the simulated kV beams 
4)      to give overview of Radiation dose to patients resulting 
from typical image-guided procedures 
5)      To discuss methods of managing and accounting for 
imaging guidance doses to radiotherapy patients 
Methods and Materials:  Although new model based 
calculation algorithms are being developed for model the 
radiation dose from low-energy x-ray beams, the Monte Carlo 
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technique is regarded as the most accurate calculation 
method in the dose calculations for kV beams. The Monte 
Carlo user code, BEAMnrc/DOSXYZnrc was used to simulate x-
ray sources. The detailed x-ray tube geometry was simulated, 
including the anode x-ray tube specifications, target design, 
beam definition, beam filtration systems, and incident 
electron energy. Each simulated realistic kV beam with 
respect of an image acquisition procedure was stored in a 
phase-space file. The simulated beam specific to an image 
procedure was individually calibrated by using anl ion 
chamber in which the air kerma calibration factor is 
traceable to national standards. When a Monte Carlo 
simulated beam is calibrated it allows the user to calculate 
both relative and absolute absorbed doses to patients. 
Patient dose calculations were done using the Monte Carlo 
generated kV beam as an incident beam on patient CT based 
images. The dose resulting from a radiograph image 
procedure was calculated by incident the source from a fixed 
incident angle (AP, RL, etc.) while the dose resulting from a 
kV-CBCT scan was calculated by rotating the X-ray source 
around the patient based on the specific scan procedure. 
Results: The Monte Carlo simulation provides realistic beam 
details such as energy spectra, particle fluence, and the 
mean energy distributions. The simulation accuracy was 
validated by benchmarking the Monte Carlo simulations 
against measurements of the beam’s half-value layers and 
dose distributions. Patient dose calculations showed that the 
imaging doses to the eyes for representative head images are 
0.05-0.2 cGy and 0.1 cGy; doses to the bladder for 
representative pelvis images are 1.6 cGy and 0.07 cGy; while 
doses to the heart for representative thorax images are 0.4 
cGy and 0.07 cGy; when using kV-CBCT scans and kV 
radiographs, respectively. In contrast, organ doses increase 
by a factor of 2-4 if bow-tie filters are not used during kV-
CBCT acquisitions.   
Conclusion: The excellent agreement between Monte Carlo 
calculations and measurements demonstrates that Monte 
Carlo techniques yield accurate results for kV dose 
calculations. Current on-board kV imaging devices result in 
much lower imaging doses compared to the conventional MV 
portal imagers. There are a variety of approaches available 
to significantly reduce the image doses. It is feasible to 
estimate and account for organ dose by using tabulated 
values based on scan procedure and site because organ doses 
from imaging procedures are only modestly dependent upon 
scan location and body size.   
   
 




SP-0602   
PSMA ligands for diagnosis and therapy  
U. Haberkorn1, J.B. Babich2, K. Kopka1, M. Eder1, M. Eisenhut1 
1DKFZ, Nuclear Medicine, Heidelberg, Germany  
2Cornell University, Nuclear Medicine, New York, USA  
   
Since the prostate-specific membrane antigen (PSMA) is 
frequently over-expressed in prostate cancer (PCa) several 
PSMA-targeting molecules are under development to detect 
and treat metastatic castration resistant prostate cancer. 
In 82.8% of 319 patients investigated with 68Ga-PSMAHBED-
PET/CT at least one lesion indicative for PCa was detected. 
Tumor detection was positively associated with PSA level and 
androgen deprivation therapy. Amongst lesions investigated 
by histology, 30 were false-negative in 68Ga-PSMAHBED-PET/CT 
(one local relapse in one patient and 29 lymph nodes in 
another patient), all other lesions (n=416) were diagnosed 
true-positive or -negative. Fifty of 116 patients available for 
follow-up received local therapy after 68Ga-PSMAHBED-PET/CT.  
A comparison of 68Ga-PSMA-ligand with 18F-
fluoromethylcholine PET/CT revealed 78 PC-suspicious lesions 
in 32 patients using 68Ga-PSMA-PET/CT and 56 lesions in 26 
patients using Choline-PET/CT. The higher detection rate in 
68Ga-PSMA-PET/CT concerning PC-suspicious lesions was 
significant (p=0.04). All lesions detected by 18F-
fluoromethylcholine-PET/CT were also seen by 68Ga-PSMA-
PET/CT. In 68Ga-PSMA-PET/CT SUVmax was clearly (>10%) 
higher in 62 of 78 lesions (79.1%) and tumor-to-background 
ratio was clearly (>10%) higher in 73 of 78 lesions (93.6%) 
when compared to 18F-fluoromethylcholine-PET/CT.  
Since the ligand bound to PSMA is internalized, the target 
may also be used for endoradiotherapy. We used a small 
molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-
[131I]-iodophenyl)ureido)-pentyl)ureido)-pentanedioic-acid; 
MIP-1095) for therapy in men with mCRPC. Dosimetry 
estimates for I-131-MIP-1095 revealed that the highest 
absorbed doses were delivered to the salivary glands (3.8 
mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). 
The absorbed dose calculated for the red marrow was 0.37 
mSv/MBq. PSA values decreased by >50% in 60.7% of the men 
treated. 84.6 % of men with bone pain showed complete or 
moderate reduction in pain. Hematological toxicities were 
mild. 25% of men treated had a transient slight to moderate 
dry mouth. No adverse effects on renal function were 
observed. 
In order to increase the therapeutic flexibilty we designed a 
novel theranostic PSMA ligand coupled to DOTA which allows 
coupling to Ga-68 for diagnostic use or to Lu-177 or Ac-225 
for therapy. Especially for alpha therapy with Ac-225 
promising results were found in the first 10 patients.  
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The integration of the full analytical power of today’s multi-
modal and multi-parametric imaging techniques into 
workflows of radiation oncology has not yet reached daily 
clinical routine. Reasons for this are manifold and range from 
simple data integration problems to the question, how the 
relevant information distributed over different images or 
over several parameters can be fused in the best way to 
provide a more complete and comprehensive image of the 
current situation. 
The EU project Software for the Use of Multi-Modality images 
in External Radiotherapy – SUMMER(*) is addressing these 
problems with the aim to extend the current set of imaging 
modalities integrated into radiotherapy planning. In this talk, 
I will give an overview over faced challenges and results 
achieved over the last 3 years from a Visual Computing 
perspective. I will show how visualization, data fusion, and 
alternative ways in data representation can be used to gain 
